Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 5/20 | 0.34 |
| ▸ | BTK | Q06187 | 5/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
| ▸ | PRKX | P51817 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TEC | P42680 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665156 | 0.80 | KDM4A (0.37) | DAO | |
| SCHEMBL1662420 | 0.77 | DAO (0.47) | DAOAKR1B1LMNALCKBTK | |
| SCHEMBL4715014 | 0.62 | MAP4K4 (0.58) | LMNAMAPK14TP53PAK4PRKX | |
| SCHEMBL7500771 | 0.61 | PCSK9 (0.53) | DAOLMNASMN1; SMN2 | |
| SCHEMBL14232830 | 0.61 | DAO (0.50) | DAOAKR1B1LMNALCKBTK | |
| SCHEMBL21729190 | 0.60 | DAO (0.47) | DAOAKR1B1LMNAP2RX7KDM4E | |
| SCHEMBL14719577 | 0.60 | DAO (0.50) | DAOAKR1B1LMNALCKBTK | |
| SCHEMBL5103941 | 0.59 | DAO (0.46) | DAOAKR1B1LCKBTKMAPK14 | |
| SCHEMBL5110657 | 0.59 | DAO (0.45) | DAOAKR1B1LCKBTKMAPK14 | |
| SCHEMBL2626804 | 0.58 | DAO (0.50) | DAOSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | claimed |
| EP-2490693-A1 | PYRAZOLO [3,4-b]PYRIDIN-4-ONE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | claimed |
| WO-2011049722-A1 | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-28 | — | — | WO | claimed |
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | CDK1, CDK5, TTBK1 | DAO 2121/4885AKR1B1 804/4885LMNA 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.